BioPharmSignal logoBioPharmSignal

Biotech News

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

Oculis (OCS)OculisClinical readout

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury and suppressed reactive astrogliosis

Related news

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

OCSOculis2026-10-20 06:00 EST

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

RHHBYRoche Holdings AG2026-10-21 12:00 EST

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

OCGNOcugen2026-10-06 11:02 EST

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

OKYOOKYO Pharma2026-10-06 11:00 EST

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

PRQRProQR Therapeutics2026-09-09 12:00 EST

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

OCGNOcugen2026-09-01 11:02 EST

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

EYPTEyePoint Pharmaceuticals2026-07-30 11:00 EST

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

OKYOOKYO Pharma2026-07-20 11:00 EST

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

EYPTEyePoint Pharmaceuticals2026-08-17 11:00 EST

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-10-22 06:00 EST

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

OCSOculis2026-10-20 06:00 EST

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

OCSOculis2026-10-19 06:00 EST

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

OCSOculis2026-10-08 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-10-07 06:00 EST

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Stock data

Close
7.87 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States